Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis

van Leeuwen, Merle M.; Doyle, Shannon; van den Belt–Dusebout, Alexandra W.; van der Mierden, Stevie; Loo, Claudette E.; Mann, Ritse M.; Teuwen, Jonas; Wesseling, Jelle

doi:10.1186/s13244-023-01529-z

Insights into Imaging

Table 2 Overview of clinicopathological factors that were assessed in the studies

From: Clinicopathological and prognostic value of calcification morphology descriptors in ductal carcinoma in situ of the breast: a systematic review and meta-analysis

Clinicopathological factors	First author, year of publication (reference)	No. of studies		No. included in meta-analysis
Clinicopathological factors	First author, year of publication (reference)	Assessed factors	Statistically significant finding	No. included in meta-analysis
Grade	Avdan Aslan, 2021 [16]; Barreau, 2005 [19]; de Roos, 2006 [20]; Dinkel, 2000 [22]; Evans, 2010 [23]; Hofvind, 2011 [24]; Holmberg, 2013 [25]; Kessar, 2002 [26]; Kong, 2020 [28]; Lee, 2021 [30]; Rauch, 2016 [34]; Rominger, 2015 [35]; Szynglarewicz, 2016 [38]; Tan, 2000 [41]; Thurfjell, 2002 [43]; Zhou, 2017 [47]	16	8	11 studies in meta-analysis
Presence (micro) invasive breast cancer	Bagnall, 2001 [18]; Lee, 2000 [29]; Nishimura, 2004 [33]; Stomper, 2003 [37]; Tabar, 2011 [40]; Thurfjell, 2002 [43]; Wang, 2019 [44]; Zhang, 2021 [46]	8	1	5 studies in meta-analysis
(Comedo)necrosis	Avdan Aslan, 2021 [16]; Barreau, 2005 [19]; Holmberg, 2013 [25]; Lee, 2021 [30]; Rauch, 2016 [34]; Szynglarewicz, 2016 [38]; Tan, 2000 [41]	7	4	5 studies in meta-analysis
Her2 overexpression	Avdan Aslan, 2021 [16]; Bae, 2013 [17]; Kim, 2015 [27]; Lee, 2021 [30]; Rominger, 2015 [35]; Zhou, 2017 [47]	6	3	4 studies in meta-analysis
ER positivity	Avdan Aslan, 2021 [16]; Bae, 2013 [17]; Kim, 2015 [27]; Lee, 2021 [30]; Rominger, 2015 [35]; Zhou, 2017 [47]	6	3	4 studies in meta-analysis
Recurrence^a	Holmberg, 2013 [25]; Rauch, 2016 [34]; Rominger, 2015 [35]; Zhou, 2017 [47]	4	1	Groups not comparable for meta-analysis
Age	Holmberg, 2013 [25]; Szynglarewicz, 2016 [38]; Zhou, 2017 [47]	3	0	Groups not comparable for meta-analysis
Ki67/proliferation	Lee, 2021 [30]; Zhou, 2017 [47]	2	0	Groups not comparable for meta-analysis
Histological size	Evans, 2010 [23]; Holmberg, 2013 [25]	2	1	Groups not comparable for meta-analysis
Neoductgenesis	Zhou, 2017 [47]; Zhou, 2014 [48]	2	1	Groups not comparable for meta-analysis
Calcification distribution	Hofvind, 2011 [24]; Szynglarewicz, 2016 [38]	2	1	Groups not comparable for meta-analysis
Margin status	de Roos, 2004 [21]	1	1	Meta-analysis N/A
Comedocarcinoma	Barreau, 2005 [19]	1	1	Meta-analysis N/A
Multicentricity	Rauch, 2016 [34]	1	0	Meta-analysis N/A
Tenascin-C	Zhou, 2017 [47]	1	1	Meta-analysis N/A
Oncotype DX score	Woodard, 2019 [45]	1	1	Meta-analysis N/A
Progression to invasive disease^a	Lilleborge, 2021 [31]	1	1	Meta-analysis N/A

^aPrognostic outcomes

Back to article page